Valuation: Evelo Biosciences, Inc.

Market Cap 11.66L 10L 9L 9L 16.06L 11Cr 16.27L 1.1Cr 43.08L 5.61Cr 43.8L 42.85L 19Cr P/E 2021
-2.63x
P/E 2022 -1.23x
Enterprise Value 43.64L 37.39L 34.98L 32.02L 60.1L 42Cr 60.89L 4.13Cr 1.61Cr 21Cr 1.64Cr 1.6Cr 69Cr EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day-80.00%
Current month-66.67%
1 month+9,900.00%
Current year-80.00%
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
7.69
5 years 0
Extreme 1.0E-6
254.8
10 years 0
Extreme 1.0E-6
398.57
Manager TitleAgeSince
Chief Executive Officer 64 21/11/2023
Director TitleAgeSince
Director/Board Member 64 21/11/2023
Date Insider Type Main position Quantity % Market Cap.
07/11/23 Fiscal year

Chief Financial Officer

14,811 0.0786%
07/11/23 Fiscal year

Chief Executive Officer

2,516 0.0134%
07/11/23 Fiscal year

Chief Technology Officer

16,413 0.0871%
Change 5-day change 1-year change 3-year change Capi.($)
-80.00%-.--%-80.00%-100.00% 18
-3.00%+2.27%+77.60%+109.33% 7.21TCr
+1.90%+23.53%+56.60%+97.76% 6.59TCr
+5.12%+25.22%+5.24%-0.82% 2.93TCr
+0.55%+1.64%-5.15%+471.68% 2.75TCr
+2.74%+12.98%+62.84%+28.14% 2.67TCr
+0.47%+6.12%+36.66%-13.79% 2.01TCr
+1.82%-6.67%+247.46%+393.10% 1.82TCr
+0.94%+3.36%+18.55%+532.94% 1.64TCr
+0.73%+5.54%+39.71%+153.07% 1.34TCr
Average -6.87%+7.53%+45.95%+167.14% 2.89TCr
Weighted average by Cap. +0.74%+9.48%+59.05%+157.80%

Financials

2021 2022
Net sales - -
Net income -12Cr -10Cr -9.79Cr -8.96Cr -17Cr -1.17TCr -17Cr -115.69Cr -45Cr -587.23Cr -46Cr -45Cr -1.94TCr -11Cr -9.81Cr -9.18Cr -8.4Cr -16Cr -1.1TCr -16Cr -108.45Cr -42Cr -550.46Cr -43Cr -42Cr -1.82TCr
Net Debt -1.21Cr -1.04Cr -97.37L -89.13L -1.67Cr -116.23Cr -1.69Cr -12Cr -4.49Cr -58Cr -4.56Cr -4.46Cr -193.12Cr 31.98L 27.39L 25.63L 23.46L 44.03L 31Cr 44.62L 3.03Cr 1.18Cr 15Cr 1.2Cr 1.17Cr 51Cr
Logo Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.
Employees
66
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. EVLO Stock